A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

​ Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: SRN001; Drug: 0.9% sodium chloride (normal saline)

Sponsors: siRNAgen Therapeutics Inc.

Recruiting Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Drug: SRN001; Drug: 0.9% sodium chloride (normal saline)
Sponsors: siRNAgen Therapeutics Inc.
Recruiting